Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 129
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00216112 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | ||
| NCT04610684 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | ||
| NCT00773474 | Lonafarnib in Metastatic Breast Cancer | ||
| NCT02382406 | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | ||
| NCT01485874 | Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | ||
| NCT03528408 | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | ||
| NCT03317158 | Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | ||
| NCT02581215 | Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer | ||
| NCT06863311 | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC | ||
| NCT00613626 | Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer | ||
| NCT05903092 | MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer | ||
| NCT04711824 | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases | ||
| NCT02581059 | Efficacy of Ginseng for Patients on Regorafenib | ||
| NCT03272217 | Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | ||
| NCT03400254 | Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") | ||
| NCT03117309 | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | ||
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | ||
| NCT01732107 | Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression | ||
| NCT00632541 | A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer | ||
| NCT03448718 | Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations | ||
| NCT07218666 | Zanzalintinib in Men With Aggressive Variant Prostate Cancer | ||
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | ||
| NCT04886531 | Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | ||
| NCT00234494 | Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer | ||
| NCT00730353 | Sutent + Taxol for Advanced Esophageal Cancer | ||
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | ||
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | ||
| NCT03547999 | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | ||
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | ||
| NCT00235235 | A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer | ||
| NCT03557918 | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | ||
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | ||
| NCT02586610 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | ||
| NCT04470674 | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients | ||
| NCT03396471 | Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary | ||
| NCT01624493 | BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients | ||
| NCT04848337 | Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer | ||
| NCT03558087 | Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing | ||
| NCT00706641 | Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder | ||
| NCT06809140 | Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | ||
| NCT00216125 | Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer | ||
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | ||
| NCT05498272 | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | ||
| NCT00216021 | Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer | ||
| NCT00216138 | Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck | ||
| NCT00216099 | Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer | ||
| NCT06493019 | Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | ||
| NCT00216073 | Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer | ||
| NCT00522665 | Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer | ||
| NCT03909334 | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
